Peripheral T-cell and NK-cell lymphomas in the WHO classification: Pearls and pitfalls

Modern Pathology

Volumn 26, Issue , 2013, Pages 71-87

  Jaffe, Elaine S ^a   Nicolae, Alina ^a   Pittaluga, Stefania ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anaplastic large cell lymphoma; Epstein Barr virus; NK cell lymphoma; Peripheral T cell lymphoma; T regulatory cells; T follicular helper cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ARTICLE; EPIDERMOTROPIC CYTOTOXIC T CELL LYMPHOMA; HEPATOSPLENIC T CELL LYMPHOMA; HODGKIN DISEASE; HUMAN; HYDROA VACCINIFORME; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MYCOSIS FUNGOIDES; NATURAL KILLER CELL LYMPHOMA; PATHOPHYSIOLOGY; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; SEROMA; SEZARY SYNDROME; SUBCUTANEOUS T CELL LYMPHOMA; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE SUBPOPULATION; WORLD HEALTH ORGANIZATION;

HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL, PERIPHERAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84871866551     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.181     Document Type: Article

References (117)

1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-4130.
2. Jaffe ES, Harris NL, Stein H, et al. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008;112:4384-4399.
3. Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med 2000;343:37-49.
4. Tripodo C, Iannitto E, Florena AM, et al. Gammadelta T-cell lymphomas. Nat Rev Clin Oncol 2009;6: 707-717.
5. Krenacs L, Smyth MJ, Bagdi E, et al. The serine protease granzymeMis preferentially expressed in NKcell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. Blood 2003;101:3590-3593.
6. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol 2003;40:175-184.
7. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003;101:3407-3412.
8. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic (gamma)(delta) T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003;102:4261-4269.
9. Garcia-Herrera A, Song JY, Chuang SS, et al. Nonhepatosplenic gammadelta T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation. Am J Surg Pathol 2011;35:1214-1225.
10. Jaffe ES. Pathobiology of peripheral T-cell lymphomas. Hematology/The Education Program of the American Society of Hematology American Society of Hematology 2006;317-322.
11. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011;29:621-663.
12. Ma CS, Deenick EK, Batten M, et al. The origins, function, and regulation of T follicular helper cells. J Exp Med 2012;209:1241-1253.
13. Roncador G, Garcia JF, Garcia JF, et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/ lymphoma. Leukemia 2005;19:2247-2253.
14. Jones D. Functional classification of peripheral T-cell lymphomas as an approach to improve outcome prediction and therapy selection. Semin Hematol 2010;47(Suppl 1):S1-S4.
15. Teruya-Feldstein J, Setsuda J, Yao X, et al. MIP-1alpha expression in tissues from patients with hemophagocytic syndrome. Lab Invest 1999;79:1583-1590.
16. Grogg KL, Attygalle AD, Macon WR, et al. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinalcenter T-helper cells? Blood 2005;106:1501-1502.
17. Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 2006;30:490-494.
18. Dunleavy K, Wilson WH, Jaffe ES. Angioimmunoblastic Tcell lymphoma: pathobiological insights and clinical implications. Curr Opin Hematol 2007;14: 348-353.
19. Delfau-Larue MH, de Leval L, Joly B, et al. Targeting intratumoral B-cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica; advance online publication, 27 February 2012; doi:10.3324/haematol.2011.061507 (e-pub ahead of print).
20. Ottaviani G, Bueso-Ramos CE, Seilstad K, et al. The role of the perifollicular sinus in determining the complex immunoarchitecture of angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2004;28:1632-1640.
21. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007;109:4952-4963.
22. Tan BT, Warnke RA, Arber DA. The frequency of Band T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn 2006;8: 466-475; quiz 527.
23. Lukes RJ, Tindle BH. Immunoblastic lymphadenopathy: a hyperimmune entity resembling Hodgkin’s disease. N Engl J Med 1975;292:1-8.
24. Frizzera G, Moran E, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinemia. Lancet 1974;i:1070-1073.
25. Lipford EH, Smith HR, Pittaluga S, et al. Clonality of angioimmunoblastic lymphadenopathy and implications for its evolution to malignant lymphoma. J Clin Invest 1987;79:637-642.
26. Weiss L, Strickler J, Dorfman R, et al. Clonal T-cell populations in angioimmunoblastic lymphadeno-pathy and angioimmunoblastic lymphadenopathylike lymphoma. Am J Pathol 1986;122:392-397.
27. Weiss LM, Jaffe ES, Liu XF, et al. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 1992;79:1789-1795.
28. Abruzzo LV, Schmidt K, Weiss LM, et al. B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. Blood 1993;82: 241-246.
29. Zettl A, Lee SS, Rudiger T, et al. Epstein-Barr virusassociated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 2002;117:368-379.
30. Quintanilla-Martinez L, Fend F, Moguel LR, et al. Peripheral T-cell lymphoma with Reed-Sternberglike cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection. Am J Surg Pathol 1999;23:1233-1240.
31. Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 2012;18:1611-1618.
32. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate antitumor immunity. Curr Opin Immunol 2012;24: 207-212.
33. Nicolae A, Plttaluga S, Venkataraman G, et al. Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: Both EBV-positive and EBV-negative variants exist. Am J Surg Pathol (in press).
34. Ohshima K, Kikuchi M, Yoshida T, et al. Lymph nodes in incipient adult T-cell leukemia-lymphoma with Hodgkin’s disease-like histologic features. Cancer 1991;67:1622-1628.
35. Venkataraman G, Berkowitz J, Morris JC, et al. Adult T-cell leukemia/lymphoma with Epstein-Barr viruspositive Hodgkin-like cells. Hum Pathol 2011;42: 1042-1046.
36. Balague O, Martinez A, Colomo L, et al. Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features. Am J Surg Pathol 2007;31:1310-1322.
37. Huppmann A, Roullet M, Raffeld M, et al. Angioimmunoblastic T-cell lymphoma partially obscured by an EBV-negative clonal plasma cell proliferation. J Clin Oncol (in press).
38. Schlegelberger B, Zhang Y, Weber-Matthiesen K, et al. Detection of aberrant clones in nearly all cases of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined interphase and metaphase cytogenetics. Blood 1994; 84:2640-2648.
39. Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012;3:3.
40. de Leval L, Savilo E, Longtine J, et al. Peripheral T-cell lymphoma with follicular involvement and a CD4þ/bcl-6þ phenotype. Am J Surg Pathol 2001;25: 395-400.
41. Agostinelli C, Hartmann S, Klapper W, et al. Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert’s personal archive. Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics. Histopathology 2011;59:679-691.
42. Lemonnier F, Couronne L, Parrens M, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 2012;120:1466-1469.
43. Streubel B, Vinatzer U, Willheim M, et al. Novel t(5;9) (q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 2006;20:313-318.
44. Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011;117: 3402-3408.
45. Rudiger T, Ichinohasama R, Ott MM, et al. Peripheral T-cell lymphoma with distinct perifollicular growth pattern: a distinct subtype of T-cell lymphoma? Am J Surg Pathol 2000;24:117-122.
46. Warnke RA, Jones D, Hsi ED. Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics. Am J Clin Pathol 2007;127:511-527.
47. Cuadros M, Dave SS, Jaffe ES, et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 2007;25: 3321-3329.
48. Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006;25:1560-1570.
49. Sonoda S, Li HC, Tajima K. Ethnoepidemiology of HTLV-1 related diseases: ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal. Cancer Sci 2011;102:295-301.
50. Tobinai K. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan. Semin Hematol 2010;47(Suppl 1): S5-S7.
51. Takatsuki K. Adult T-cell leukemia. Intern Med 1995; 34:947-952.
52. Jaffe ES, Blattner WA, Blayney DW, et al. The pathologic spectrum of adult T-cell leukemia/lymphoma in the United States. Am J Surg Pathol 1984; 8:263-275.
53. Abe M, Uchihashi K, Kazuto T, et al. Foxp3 expression on normal and leukemic CD4þCD25þ T cells implicated in human T-cell leukemia virus type-1 is inconsistent with Treg cells. Eur J Haematol 2008;81:209-217.
54. Satou Y, Utsunomiya A, Tanabe J, et al. HTLV-1 modulates the frequency and phenotype of FoxP3þ CD4þ T cells in virus-infected individuals. Retrovirology 2012;9:46.
55. Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 2001;14:219-228.
56. Falini B, Pulford K, Pucciarini A, et al. Lymphomas expressing ALK fusion protein(s) other than NPMALK. Blood 1999;94:3509-3515.
57. Lamant L, McCarthy K, d’Amore E, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lym-phoma: results of the ALCL99 study. J Clin Oncol 2011;29:4669-4676.
58. Wellmann A, Thieblemont C, Pittaluga S, et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large cell lymphomas (ALCL). Blood 2000;96:398-404.
59. Savage KJ, Harris NL, Vose JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALKþ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-5504.
60. Feldman AL, Law ME, Inwards DJ, et al. PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus. Mod Pathol 2010;23:593-602.
61. Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALKnegative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 2011;117: 915-919.
62. Barry TS, Jaffe ES, Sorbara L, et al. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol 2003;27:1513-1522.
63. Miranda RN, Lin L, Talwalkar SS, et al. Anaplastic large cell lymphoma involving the breast a clinicopathologic study of 6 cases and review of the literature. Arch Pathol Lab Med 2009;133:1383-1390.
64. de Jong D, Vasmel WL, de Boer JP, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA 2008;300:2030-2035.
65. Roden AC, Macon WR, Keeney GL, et al. Seromaassociated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. Mod Pathol 2008;21: 455-463.
66. Brody GS. Brief recommendations for dealing with a new case of anaplastic large T-cell lymphoma. Plast Reconstr Surg 2012;129:871e-872ee.
67. Thompson PA, Lade S, Webster H, et al. Effusionassociated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinicopathological entity. Haematologica 2010;95:1977-1979.
68. Aladily TN, Medeiros LJ, Amin MB, et al. Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. Am J Surg Pathol 2012;36: 1000-1008.
69. Eberle FC, Song JY, Xi L, et al. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma. Am J Surg Pathol 2012;36:716-725.
70. Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol 2011;24:596-605.
71. Sciallis AP, Law ME, Inwards DJ, et al. Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders. Mod Pathol 2012;25: 983-992.
72. Gagari E, Stathopoulos P, Katsambas A, et al. Traumatic ulcerative granuloma with stromal eosinophilia: a lesion with alarming histopathologic presentation and benign clinical course. Am J Dermatopathol 2011;33:192-194.
73. Salisbury CL, Budnick SD, Li S. T-cell receptor gene rearrangement and CD30 immunoreactivity in traumatic ulcerative granuloma with stromal eosinophilia of the oral cavity. Am J Clin Pathol 2009;132:722-727.
74. Hwang ST, Janik JE, Jaffe ES, et al. Mycosis fungoides and Sezary syndrome. Lancet 2008;371:945-957.
75. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-1722.
76. Massone C, Kodama K, Kerl H, et al. Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol 2005;29:550-560.
77. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53:1053-1063.
78. Braun FC, Grabarczyk P, Mobs M, et al. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sezary syndrome. Leukemia 2011;25:1494-1501.
79. Narducci MG, Arcelli D, Picchio MC, et al. Micro-RNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death Dis 2011;2:e151.
80. Kumar S, Krenacs L, Medeiros J, et al. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum Pathol 1998;29:397-403.
81. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 1998;22:881-893.
82. Mehta N, Wayne AS, Kim YH, et al. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clin Lymphoma Myeloma Leuk 2012;12:20-25.
83. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785.
84. Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008;111:838-845.
85. Pincus LB, LeBoit PE, McCalmont TH, et al. Subcutaneous panniculitis-like T-cell lymphoma with overlapping clinicopathologic features of lupus erythematosus: coexistence of 2 entities? Am J Dermatopathol 2009;31:520-526.
86. Toro JR, Beaty M, Sorbara L, et al. gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch Dermatol 2000;136:1024-1032.
87. Saggini A, Gulia A, Argenyi Z, et al. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8þ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol 2010;34:1168-1175.
88. Cardoso J, Duhra P, Thway Y, et al. Lymphomatoid papulosis type D: a newly described variant easily confused with cutaneous aggressive CD8-positive cytotoxic T-cell lymphoma. Am J Dermatopathol 2012;34:762-765.
89. Garcia-Herrera A, Colomo L, Camos M, et al. Primary cutaneous small/medium CD4þ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol 2008;26:3364-3371.
90. Grogg KL, Jung S, Erickson LA, et al. Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol 2008;21:708-715.
91. Beltraminelli H, Leinweber B, Kerl H, et al. Primary cutaneous CD4þ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am J Dermatopathol 2009;31:317-322.
92. Cetinozman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol 2012;36:109-116.
93. Rodriguez Pinilla SM, Roncador G, Rodriguez-Peralto JL, et al. Primary cutaneous CD4þ small/mediumsized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol 2009;33: 81-90.
94. Delabie J, Holte H, Vose JM, et al. Enteropathyassociated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood 2011;118:148-155.
95. Chan JK, Chan AC, Cheuk W, et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent gammadelta T-cell receptor expression. Am J Surg Pathol 2011;35:1557-1569.
96. Sun J, Lu Z, Yang D, et al. Primary intestinal T-cell and NK-cell lymphomas: a clinicopathological and molecular study from China focused on type II enteropathy-associated T-cell lymphoma and primary intestinal NK-cell lymphoma. Mod Pathol 2011;24:983-992.
97. Pongpruttipan T, Sukpanichnant S, Assanasen T, et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and alphabeta, gammadelta, and alphabeta/gammadelta T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol 2012;36:481-499.
98. Cooke CB, Krenacs M, Stetler-Stevenson M, et al. Hepatosplenic gamma/delta T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma/ delta T-cell origin. Blood 1996;88:4265-4274.
99. Veres G, Baldassano RN, Mamula P. Infliximab therapy for pediatric Crohn’s disease. Expert Opin Biol Ther 2007;7:1869-1880.
100. Herrinton LJ, Liu L, Abramson O, et al. The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006. Pharmacoepidemiol Drug Saf 2012;21:49-52.
101. Travert M, Huang Y, de Leval L, et al. Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood 2012;119: 5795-5806.
102. Jaffe ES, Chan JK, Su IJ, et al. Report of the workshop on nasal and related extranodal angiocentric T/ natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996;20:103-111.
103. Chiang AK, Tao Q, Srivastava G, et al. Nasal NK-and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin’s disease. Int J Cancer 1996;68:285-290.
104. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009;113:3931-3937.
105. Arber DA, Weiss LM, Albujar PF, et al. Nasal lymphomas in Peru. High incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am J Surg Pathol 1993;17:392-399.
106. Elenitoba-Johnson KSJ, Zarate-Osorno A, Meneses A, et al. Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Mod Pathol 1998; 11:754-761.
107. Ho FC, Choy D, Loke SL, et al. Polymorphic reticulosis and conventional lymphomas of the nose and upper aerodigestive tract: a clinicopathologic study of 70 cases, and immunophenotypic studies of 16 cases. Hum Pathol 1990;21:1041-1050.
108. Liang R. Diagnosis and management of primary nasal lymphoma of T-cell or NK-cell origin. Clin Lymphoma 2000;1:33-37; discussion 8.
109. Iqbal J, Weisenburger DD, Chowdhury A, et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia 2011;25:348-358.
110. Wong N, Wong KF, Chan JK, et al. Chromosomal translocations are common in natural killer-cell lymphoma/leukemia as shown by spectral karyotyping. Hum Pathol 2000;31:771-774.
111. Cohen JI, Kimura H, Nakamura S, et al. Epstein-Barr virus-associated lymphoproliferative disease in nonimmunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 2009;20:1472-1482.
112. Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 2012;119:673-686.
113. Quintanilla-Martinez L, Kumar S, Fend F, et al. Fulminant EBV(þ) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood 2000;96:443-451.
114. Gupta G, Man I, Kemmett D. Hydroa vacciniforme: a clinical and follow-up study of 17 cases. J Am Acad Dermatol 2000;42:208-213.
115. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 2002;10:7-14.
116. Tokura Y, Ishihara S, Tagawa S, et al. Hypersensitivity to mosquito bites as the primary clinical manifestation of a juvenile type of Epstein-Barr virus-associated natural killer cell leukemia/lymphoma. J Am Acad Dermatol 2001;45:569-578.
117. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 2006;16:251-261.